ASX Announcement

First implant at Pennsylvania State University

Sydney, 5 May 2010

Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for advanced heart failure, announced that on Friday, 30 April Pennsylvania State University successfully completed an implant of the Company’s C-Pulse™ heart assist system in a patient under a clinical trial approved by the US Food and Drug Administration (FDA). This patient, whose progress is as expected, is the first implanted at Pennsylvania State University and the sixth patient to be treated with the C-Pulse heart assist system.

About Sunshine Heart

Sunshine Heart (ASX: SHC) (www.sunshineheart.com) is a global medical device company, committed to the commercialization of C-Pulse™ an implantable, non-blood contacting, heart assist therapy for the treatment of people with moderate heart failure. C-Pulse reduces the symptoms of heart failure through the use of counterpulsation technology which enables an increase in cardiac output, an increase in coronary blood flow and reduction in the heart’s pumping load. The Company has received approval from the US Food and Drug Administration (FDA) to conduct a 20 person US clinical trial with C-Pulse and patient enrolment has commenced. Sunshine Heart listed on the ASX in September 2004 has a presence in Australia, New Zealand and the United States of America.

For further information, please visit www.sunshineheart.com or contact:

Contact:
Dave Rosa
CEO
+1 952 237 7412
dave.rosa@sunshineheart.com

Rowena Hubble
Company Secretary
+61 2 8424 7700
rowena.hubble@sunshineheart.com

This press release may contain forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties from time to time in the Company’s filings with the Australian Securities Exchange.